DexCom Glucose Monitors' National Coverage Could Support H2 Upside, RBC Capital Markets Says

MT Newswires Live07-31 23:55

DexCom's (DXCM) upcoming national coverage determination for its continuous glucose monitoring system and strong demand momentum could support an even more positive H2 outlook, RBC Capital Markets said in a note Friday.

The company's G7 15-day CGM is now accessible to adult G7 customers in the US following the availability of Tandem's (TNDM) Tandem Mobi automated insulin pump, and management is on track to convert nearly 50% of its US installed base by year-end, according to the note.

The investment firm said the combination of expanded G7 access, product cycle momentum, and improving customer satisfaction positions the company for potential US upside in H2.

International markets remain crucial to DexCom's growth story, with global new starts matching prior-quarter records and G7 15-day cleared in Canada, the firm said, adding that it sees the 15-day rollout as a key driver for consistent double-digit international growth.

RBC Capital Markets kept an outperform rating on DexCom and raised its price target to $90 from $85.

Shares of DexCom were up about 11% in Friday trading.

Price: 82.72, Change: +8.18, Percent Change: +10.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656398687?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 23:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656398687","market":"us","top_or_hot":-1,"title":"DexCom Glucose Monitors' National Coverage Could Support H2 Upside, RBC Capital Markets Says","media":"MT Newswires Live","content":"<html><body><p> DexCom's (DXCM) upcoming national coverage determination for its continuous glucose monitoring system and strong demand momentum could support an even more positive H2 outlook, RBC Capital Markets said in a note Friday.</p><p>The company's G7 15-day CGM is now accessible to adult G7 customers in the US following the availability of Tandem's (TNDM) Tandem Mobi automated insulin pump, and management is on track to convert nearly 50% of its US installed base by year-end, according to the note.</p><p>The investment firm said the combination of expanded G7 access, product cycle momentum, and improving customer satisfaction positions the company for potential US upside in H2.</p><p>International markets remain crucial to DexCom's growth story, with global new starts matching prior-quarter records and G7 15-day cleared in Canada, the firm said, adding that it sees the 15-day rollout as a key driver for consistent double-digit international growth.</p><p>RBC Capital Markets kept an outperform rating on DexCom and raised its price target to $90 from $85.</p><p>Shares of DexCom were up about 11% in Friday trading.</p><p>Price: 82.72, Change: +8.18, Percent Change: +10.97</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DexCom Glucose Monitors' National Coverage Could Support H2 Upside, RBC Capital Markets Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDexCom Glucose Monitors' National Coverage Could Support H2 Upside, RBC Capital Markets Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-31 23:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> DexCom's (DXCM) upcoming national coverage determination for its continuous glucose monitoring system and strong demand momentum could support an even more positive H2 outlook, RBC Capital Markets said in a note Friday.</p><p>The company's G7 15-day CGM is now accessible to adult G7 customers in the US following the availability of Tandem's (TNDM) Tandem Mobi automated insulin pump, and management is on track to convert nearly 50% of its US installed base by year-end, according to the note.</p><p>The investment firm said the combination of expanded G7 access, product cycle momentum, and improving customer satisfaction positions the company for potential US upside in H2.</p><p>International markets remain crucial to DexCom's growth story, with global new starts matching prior-quarter records and G7 15-day cleared in Canada, the firm said, adding that it sees the 15-day rollout as a key driver for consistent double-digit international growth.</p><p>RBC Capital Markets kept an outperform rating on DexCom and raised its price target to $90 from $85.</p><p>Shares of DexCom were up about 11% in Friday trading.</p><p>Price: 82.72, Change: +8.18, Percent Change: +10.97</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4207","symbol_name":"综合性银行","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656398687","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656398687","pubTimestamp":1785513309,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"DexCom's  upcoming national coverage determination for its continuous glucose monitoring system and strong demand momentum could support an even more positive H2 outlook, RBC Capital Markets said in a note Friday.The company's G7 15-day CGM is now accessible to adult G7 customers in the US following the availability of Tandem's  Tandem Mobi automated insulin pump, and management is on track to convert nearly 50% of its US installed base by year-end, according to the note.The investment firm said the combination of expanded G7 access, product cycle momentum, and improving customer satisfaction positions the company for potential US upside in H2.International markets remain crucial to DexCom's growth story, with global new starts matching prior-quarter records and G7 15-day cleared in Canada, the firm said, adding that it sees the 15-day rollout as a key driver for consistent double-digit international growth.RBC Capital Markets kept an outperform rating on DexCom and raised its price ta","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4207":"综合性银行","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","GSIB":"THEMES GLOBAL SYSTEMICALLY IMPORTANT BANKS ETF","BK4551":"寇图资本持仓","DXCM":"德康医疗","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","EKG":"First Trust Nasdaq Lux Digital Health Solutions ETF","NHLD":"National Holdings Corporation","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","TNDM":"Tandem Diabetes","BK4082":"医疗保健设备","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4504":"桥水持仓","HEAL":"Global X HealthTech ETF","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4588":"碎股","BK4548":"巴美列捷福持仓","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC"},"translate_title":"加拿大皇家银行资本市场表示，DexCom 血糖监测仪的全国覆盖范围可能会支持 H2 的上涨空间","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXCM":1.5,"GSIB":0.6,"HEAL":0.6,"EKG":0.6,"TNDM":1,"NHLD":1.5},"content_text":"DexCom's (DXCM) upcoming national coverage determination for its continuous glucose monitoring system and strong demand momentum could support an even more positive H2 outlook, RBC Capital Markets said in a note Friday.The company's G7 15-day CGM is now accessible to adult G7 customers in the US following the availability of Tandem's (TNDM) Tandem Mobi automated insulin pump, and management is on track to convert nearly 50% of its US installed base by year-end, according to the note.The investment firm said the combination of expanded G7 access, product cycle momentum, and improving customer satisfaction positions the company for potential US upside in H2.International markets remain crucial to DexCom's growth story, with global new starts matching prior-quarter records and G7 15-day cleared in Canada, the firm said, adding that it sees the 15-day rollout as a key driver for consistent double-digit international growth.RBC Capital Markets kept an outperform rating on DexCom and raised its price target to $90 from $85.Shares of DexCom were up about 11% in Friday trading.Price: 82.72, Change: +8.18, Percent Change: +10.97","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656398687","isCrawlerRequest":true}